The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor

Thrombosis and Haemostasis

Volumn 102, Issue 3, 2009, Pages 460-468

  Verkleij, Chantal J N ^a   Nieuwdorp, Max ^a   Gerdes, Victor E A ^a,b   Mörgelin, Matthias ^c   Meijers, Joost C M ^a   Marx, Pauline F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Cardiovascular disease; Diabetes mellitus; Hyperglycaemia; Protein glycation; TAFI

Indexed keywords

GLYCERALDEHYDE; HEMOGLOBIN A1C; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOSE RESPONSE; FIBRINOLYSIS; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION;

CARBOXYPEPTIDASE U; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRINOLYSIS; GLUCOSE CLAMP TECHNIQUE; GLYCERALDEHYDE; HUMANS; HYPERGLYCEMIA; MALE; THROMBIN; THROMBOMODULIN; TIME FACTORS;

EID: 70449338765     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0016     Document Type: Article

References (33)

1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. (Pubitemid 28350165)
2. Grant PJ . Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
3. Sobel BE . Effects of glycemic control and other determinants on vascular disease in type 2 diabetes. Am J Med 2002; 113 (Suppl 6A): 12S-22S.
4. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32: 269-273. (Pubitemid 37490551)
5. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in noninsulin- dependent diabetes mellitus. Ann Med 1996; 28: 371-380. (Pubitemid 26268257)
6. Fuller JH, Keen H, Jarrett RJ, et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966. (Pubitemid 10244349)
7. Kannel WB, D'Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-676. (Pubitemid 20312600)
8. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. J Am Med Assoc 2000; 283: 221-228.
9. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907. (Pubitemid 30840139)
10. Nilsson TK, Boman K, Bjerle P, et al. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994; 235: 419-423. (Pubitemid 24212805)
11. Juhan-Vague I, Roul C, Alessi MC, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373. (Pubitemid 19168139)
12. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
13. Hori Y, Gabazza EC, Yano Y, et al. insulin resistance is associated with iincreased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metabolism 2002; 87: 660-665. (Pubitemid 34158234)
14. Rigla M, Wagner AM, Borrell M, et al. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metabolism 2006; 55: 1437-1442.
15. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
16. Bajzar L . Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
17. Wang W, Boffa M, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181. (Pubitemid 28500426)
18. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
19. Usui T, Shimohira K, Watanabe H, et al. Detection and determination of glyceraldehyde-derived advanced glycation end product. Biofactors 2004; 21: 391-394. (Pubitemid 40921890)
20. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-1206. (Pubitemid 40909657)
21. Dunn EJ, Philippou H, Ariens RA, et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
22. Nieuwdorp M, van Haeften TW, Gouverneur MC, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55: 480-486. (Pubitemid 43343279)
23. Mosnier LO, Von dem Borne PA, Meijers JC, et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
24. Marx PF, Hackeng TM, Dawson PE, et al. Inactivation of activated thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-12415.
25. Pahlman LI, Marx PF, Morgelin M, et al. Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J Biol Chem 2007; 282: 24873-24881. (Pubitemid 47347522)
26. Willemse J, Leurs J, Verkerk R, et al. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate. Anal Biochem 2005; 340: 106-112. (Pubitemid 40404106)
27. Schatteman KA, Goossens FJ, Scharpé SS, et al. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-813.
28. Rouser G, Fleisher S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-496.
29. Brunner J, Skrabal P, Hauser H. Single bilayer vesicles prepared without sonication. Physico-chemical porperties. Biochim Biophys Acta 1976; 455: 322-331.
30. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94. (Pubitemid 29197147)
31. Bobbink IW, De Boer HC, Tekelenburg WL, et al. Effect of extracellular matrix glycation on endothelial cell adhesion and spreading: involvement of vitronectin. Diabetes 1997; 46: 87-93.
32. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
33. Valnickova Z, Thogersen IB, Christensen S, et al. Activated human plasma carboxypeptidase B is retained in the blood by binding to α2-macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-12943. (Pubitemid 26175868)